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Abstract
Fatigue is one of the most debilitating symptoms for people with multiple sclerosis (PwMS). By consolidating a diverse 
and conflicting evidence-base, this systematic review and meta-analysis aimed to gain new insights into the neurobiology 
of MS fatigue. MEDLINE, ProQuest, CINAHL, Web of Science databases and grey literature were searched using Medical 
Subject Headings. Eligible studies compared neuroimaging and neurophysiological data between people experiencing high 
(MS-HF) versus low (MS-LF) levels of perceived MS fatigue, as defined by validated fatigue questionnaire cut-points. Data 
were available from 66 studies, with 46 used for meta-analyses. Neuroimaging studies revealed lower volumetric measures 
in MS-HF versus MS-LF for whole brain ( 22.74 ml; 95% CI: -37.72 to -7.76 ml; p = 0.003), grey matter ( 18.81 ml; 95% CI: 
 29.60 to  8.03 ml; p < 0.001), putamen ( 0.40 ml; 95% CI:  0.69 to  0.10 ml; p = 0.008) and acumbens ( 0.09 ml; 95% CI:  0.15 to 
 0.03 ml; p = 0.003) and a higher volume of T1-weighted hypointense lesions (1.10 ml; 95% CI: 0.47 to 1.73 ml; p < 0.001). 
Neurophysiological data showed reduced lower-limb maximum voluntary force production ( 19.23 N; 95% CI:  35.93 to 
 2.53 N; p = 0.02) and an attenuation of upper-limb ( 5.77%; 95% CI: 8.61 to  2.93%; p < 0.0001) and lower-limb ( 2.16%; 95% 
CI: 4.24 to  0.07%; p = 0.04) skeletal muscle voluntary activation, accompanied by more pronounced upper-limb fatigability 
( 5.61%; 95% CI: -9.57 to -1.65%; p = 0.006) in MS-HF versus MS-LF. Results suggest that MS fatigue is characterised by 
greater cortico-subcortical grey matter atrophy and neural lesions, accompanied by neurophysiological decrements, which 
include reduced strength and voluntary activation.
Prospero registration Prospero registration number: CRD42016017934
Keywords Multiple sclerosis · Neuroimaging · Neurostructural · Fatigue · Neurophysiology
Introduction
Studies show that ≥ 75% of people with multiple sclero-
sis (PwMS) experience fatigue symptoms persistently or 
sporadically (Lerdal et al., 2007) and over half the MS 
population describe it as their most severe symptom 
(Fisk  et al., 1994a). In proposing a unified taxonomy 
for fatigue in neurologic illness, (Kluger et  al., 2013) 
highlighted the importance of differentiating between 
perceived fatigue and fatigability and the application of 
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neuroimaging, neurophysiology and neuropathologic 
measures to improve our understanding of these two con-
structs was identified as a research priority. Perceived 
fatigue includes subjective feelings of weariness and an 
increased subjective perception of effort for everyday tasks 
(irrespective of recent physical exertion) and is commonly 
rated in PwMS with the Fatigue Severity Scale (FSS) and 
Modified Fatigue Impact Scale (MFIS) (Fisk et al., 1994b; 
Krupp et  al., 1989). The FSS is a 9-item scale which 
focuses on the severity, frequency and impact of fatigue 
on daily life during the past seven days, whereas the MFIS 
is a 21-item scale yielding data on the level of cognitive, 
physical, psychosocial and total fatigue experienced dur-
ing the past 4 weeks. Validated cut-points of > 4 and ≥ 38 
for the FSS (Krupp et al., 1995) and MFIS (Flachenecker 
et al., 2002), respectively, have been used to classify peo-
ple experiencing higher (MS-HF) versus lower (MS-LF) 
levels of perceived MS fatigue. However, other threshold 
scores have been used as the criterion for higher levels 
of perceived fatigue in some studies (Dezza et al., 2015; 
Colombo et  al., 2000; Niepel et  al., 2006; Tomasevic 
et al., 2013). In contrast, fatigability, sometimes referred 
to as motor fatigability or performance fatigability, which 
can include cognitive performance deficits (Kluger et al., 
2013; Severijns et al., 2017; Zijdewind et al., 2016), is 
defined as the rate of change in a performance criterion. 
Examples include a reduction in maximum voluntary con-
traction (MVC) force in the motor domain and an objective 
change in cognitive performance in the cognitive domain. 
Fatigability during motor and cognitive tasks was divided 
into central and peripheral components by Kluger et al. 
(2013). Central fatigue was discussed in terms of central 
nervous system causes of fatigability, whereas peripheral 
fatigue relates to fatigability resulting from changes at or 
distal to the neuromuscular junction (Kluger et al., 2013).
Neuroimaging studies that have investigated associa-
tions between perceived fatigue severity and morphomet-
ric measures of global brain atrophy or regional atrophy 
within grey or white matter structures have yielded con-
flicting results (Gomez et al., 2013; Pellicano et al., 2010; 
Rocca et al., 2014; Tedeschi et al., 2007). Nevertheless, 
evidence of impaired functional connectivity between 
cortical and sub-cortical regions, implicates basal gan-
glia structures, the thalamus, and specific areas within 
the frontal, parietal, and temporal lobes in perceived MS 
fatigue (Filippi et al., 2002; Jaeger et al., 2018; Roelcke 
et al., 1997; Tartaglia et al., 2004; Wilting et al., 2016). 
Although neuromuscular studies have yielded inconsist-
ent data for voluntary activation (VA) of the upper- and 
lower-limb skeletal muscles in PwMS versus healthy con-
trols (Andreasen et al., 2009; Ng et al., 2000; Steens et al., 
2012a), neurophysiological impairments could underpin 
the reductions in MVC force (Liepert et al., 2005; Ng 
et al., 2004; Wolkorte et al., 2016) and motor function 
(Ng et al., 2004) and the more pronounced levels of fati-
gability (Liepert et al., 2005; Sheean et al., 1997; Wolkorte 
et al., 2016) that have been reported in PwMS. Such neu-
rophysiological changes are likely to have a direct bearing 
on perceived effort for everyday tasks and perceptions of 
fatigue amongst PwMS.
The aim of this systematic review and meta-analysis 
was to investigate neurostructural and maladaptive neu-
rophysiological connectivity differences between MS-HF 
and MS-LF, including motor fatigability. As cognitive 
functioning is acknowledged as being a complex phenom-
enon with multifactorial hierarchical domains and numer-
ous approaches to measurement, cognitive performance 
fatigability was considered to be outside the scope of this 
research. Current knowledge on the underlying neurobio-
logical substrate of MS fatigue, as assessed by neuroimaging 
and neurophysiological measures, is impeded by inconsist-
ent findings, insufficiently powered cross-sectional stud-
ies and comparisons between healthy controls and PwMS, 
without partitioning the latter by fatigue status. This makes 
it difficult to draw definitive conclusions about neurobiologi-
cal differences between MS-HF and MS-LF and there is a 
need to consolidate an extensive and somewhat conflicting 
evidence-base. This systematic review and accompanying 
meta-analyses addressed these limitations by synthesizing 
all current evidence, including peer-reviewed (published) 
neuroimaging and neurophysiological data acquired from 
senior authors which were not originally presented by fatigue 
status of PwMS in the published report. By meta-analysing 
previously reported dichotomised data for MS-HF versus 
MS-LF, the main aim was to gain an improved insight into 
structural and neurophysiological correlates of MS fatigue.
Methods
Search Strategy
This systematic review and meta-analysis was conducted 
in accordance with the preferred reporting items for sys-
tematic reviews and meta-analyses (PRISMA) statement 
(Liberati et al., 2009) and the protocol was pre-registered 
with the PROSPERO International Prospective Register of 
Systematic Reviews (https:// www. crd. york. ac. uk/ prosp ero/ 
displ ay_ record. php? Recor dID= 17934). A systematic lit-
erature search of PubMed/MEDLINE, ProQuest, CINAHL 
and Web of Science from inception until 31 December 2019 
was undertaken, blinded to title and authorship, by two 
reviewers (PE & SG). The search strategy was conducted 
using Medical Subject Headings (MeSH) and search terms 
included those related to MS, fatigue, neurophysiology, neu-
roimaging, MVC, motor nerve stimulation (Supplementary 
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Table 1). We also searched the grey literature (theses, con-
ference abstracts/posters), along with the reference lists of 
retrieved systematic reviews and included studies to identify 
other pertinent articles.
Study Selection
Eligible articles reported data from cross-sectional studies 
using a validated fatigue scale and defined cut-points for 
differentiating MS-HF from MS-LF. Adults > 18 years with 
definite multiple sclerosis (Poser or McDonald criteria) and 
all types of MS (relapsing–remitting [RR]; secondary pro-
gressive [SP]; primary progressive [PP]) were eligible for 
inclusion. The included studies must have reported neuroim-
aging measures or neurophysiological variables for MS-HF 
and MS-LF. However, 14 authors of 16 peer-reviewed pub-
lished studies provided original data (neurofunctional or 
neurophysiological) partitioned by perceived fatigue status 
of PwMS (MS-HF versus MS-LF), where it was available 
but not reported as such in the published article, and these 
authors have been acknowledged. In the case of the same 
cohort data being reported in > 1 article, only the most recent 
publication was included. Non-English animal studies, case 
studies, review articles, randomised controlled trials and 
other controlled trials, pharmacological trials and studies 
that only reported other physical/psychological outcomes 
(e.g. gait analysis variables, mental health status, disability, 
cognitive impairment and spiro-ergometric) were excluded.
Methodological Quality Assessment
The methodological quality of included studies was evalu-
ated using the Cross-Sectional/Prevalence Study Quality 
Scale, recommended by the Agency for Healthcare Research 
and Quality (AHRQ: http:// www. ncbi. nlm. nih. gov/ books/ 
NBK35 156/) (Zeng et al., 2015). The AHRQ scale is an 
11-item tool that is used to evaluate study quality, with an 
item scoring “1” if it was answered “Yes” and “0” if it was 
answered “No”, “Unclear” or “Not Applicable”. Scores of 
0–3 indicate “low quality”, 4–7 “moderate quality” and 8–11 
“high quality” (Supplementary Table 2). Two reviewers (PE 
and SG) assessed each included study independently, with 
disagreements being resolved by consensus and the opinion 
of a third reviewer (JS).
Data Extraction and Analysis
Data were extracted independently by three reviewers (PE, 
SG and JS) as follows: (1) Study design; (2) Characteris-
tics of the participants (number, subtype of MS, disease 
duration, age, gender and Expanded Disability Status Scale 
[EDSS] score, fatigue score); (3) Primary outcomes; (4) Sec-
ondary outcomes. Means and standard deviations for each 
variable were extracted for meta-analyses using RevMan 5.0 
(http:// www. cc- ims. net/ RevMan/ downl oad. htm). Due to var-
iation in clinical or demographic characteristics and fatigue 
assessments across studies, a random-effects model was 
applied throughout, and meta-analyses were not guided by 
the quality assessment data for individual included studies. 
A p value < 0.05 indicated statistical significance for an over-
all effect and the magnitude of heterogeneity across studies 
was tested using the I2 statistic: I2 values < 25%, 25–50%, 
or > 50% indicate low, moderate and high heterogeneity, 
respectively (Higgins et al., 2003). Funnel plots were not 
constructed, owing to the number of meta-analyses which 
included < 10 studies (Sutton et al., 2000). Sub-group analy-
ses were planned based on brain region and limb targeted. 
Data were not included in meta-analyses if means, stand-
ard deviations and number of participants allocated to each 
group were not reported or available.
Results
Figure 1 shows that the search yielded 66 studies, with data 
from 46 studies included in meta-analyses (42 neuroimaging 
studies, 19 neurophysiological studies and five combined 
neuroimaging and neurophysiological studies). Supplemen-
tary Tables 3a and 3b present details of each included study. 
A total of 1761 MS-HF and 1391 MS-LF participants were 
compared in the cross-sectional studies, with the majority 
(2345) having a definite RRMS diagnosis, 150 being classi-
fied as PPMS or SPMS and 575 participants of unspecified 
disease type. In 48 studies, healthy controls were included as 
an additional comparison. Studies which provided details of 
the gender balance for MS-HF and MS-LF (N = 43) showed 
there were approximately twice as many women than men in 
each subgroup (729:357 and 657:387, respectively), reflect-
ing the higher prevalence of MS amongst women (Harbo 
et al., 2013). The MS-HF and MS-LF groups were well- 
balanced for age, disease duration and EDSS score. The mean 
age was 40 years for MS-HF versus 38 years for MS-LF 
(reported in 56 studies). MS-HF had a mean disease duration 
(years) and EDSS score of 8.7 years (reported in 41 studies) 
and 2.6 (reported in 52 studies) respectively, versus 8.1 years 
and 2.0, respectively for MS-LF. EDSS scores indicated a 
mild to moderate level of disability with no impairment to 
walking for the majority of MS-HF and MS-LF participants 
(EDSS ≤ 3.5 in 85% of studies).
Perceived Fatigue Measures
The most frequently used scale to differentiate MS-HF from 
MS-LF was the FSS (Krupp et al., 1989), which was used 
in 48 of the included studies, using mean cut-off scores for 
MS-HF of > 4 or > 5 and total scores ranging from > 25 
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to > 36. A further 10 studies used the MFIS (Fisk et al., 
1994a) with cut-off scores for MS-HF in the range of > 35 
to > 38 or ≥ 16 for the MFIS physical scale. Three studies 
used the cognitive scale of the Fatigue Scale for Motor and 
Cognitive Functions using cut-points in the range of ≥ 22 
to ≥ 28 (Pravata et al., 2016; Sander et al., 2016; Wilting 
et al., 2016). These studies were included because they 
reported regional brain volume or functional connectivity 
data and two of them provided evidence that high levels of 
cognitive fatigue are accompanied by higher levels of motor 
fatigue (Pravata et al., 2016; Sander et al., 2016). Two fur-
ther studies used the MFIS-5 and EMIF-SEP (a validated 
French version of the Fatigue Impact Scale) and three stud-
ies used subjective perceptions to classify MS-HF, e.g. 
“mostly or daily tired” (Supplementary Tables 3a and 3b).
Neuroimaging and Neurophysiological Measures
Neuroimaging measures for meta-analyses were obtained 
using magnetic resonance imaging (MRI), diffusion ten-
sor imaging (DTI) and magnetic resonance spectroscopy 
(MRS). Measures included total normalised brain volume, 
grey and white matter volumes, T1-weighted hypointense 
and T2-weighted lesion volumes, white matter microstruc-
tural integrity (DTI indices of fractional anisotropy and 
mean diffusivity) and neuronal/axonal integrity and func-
tion (N-acetylaspartate to creatine [NAA/Cr] ratio and cho-
line to creatine [Cho/cr] ratio by MRS). Neurophysiological 
measures for meta-analyses were obtained using transcra-
nial magnetic stimulation (TMS), electroencephalography 
(EEG), neuromuscular electrical stimulation (NMES) and 
electromyography (EMG) and included motor evoked poten-
tial (MEP) amplitude, MEP latency, MEP threshold, central 
motor conduction time, short-interval intracortical inhibition 
(SICI), and voluntary activation (central motor drive) using 
the twitch-interpolation technique during MVC (Merton, 
1954). Brain region functional connectivity data determined 
using functional MRI (fMRI) were not included in meta-
analyses but the key findings are reported in Supplementary 
Table 3a. MVC force data were determined using upper- or 
lower-limb rigs that fixed the joint in position for isometric 
muscle actions, with motor fatigability being assessed using 
a sustained MVC or intermittent %MVC isometric fatiguing 
protocol and reported as percent of the baseline force.
Meta‑Analyses Overview
The results of meta-analyses are presented as absolute mean 
differences with 95% confidence intervals (CI) in Table 1. 
Table 1 also presents the number of studies and number 
of participants in the MS-HF and MS-LF groups for each 
meta-analysis. Detailed forest plots showing comparisons 
of MS-HF versus MS-LF, MS-HF versus HC and MS-LF 
versus HC are presented in Supplementary Figs. 1, 2 and 3. 
A summary of meta-analyses results for all neuroimaging 
and neurophysiological variables (MS-HF versus MS-LF) 
are presented as standardised mean difference (SMD) and 
95% CI in Fig. 2, with Cohen’s categories (SMD = 0.2–0.5; 
0.5–0.8; ≥ 0.8) indicating small, medium and large overall 
effect sizes, respectively.
Quality Assessment
Most of the included studies (70%) were classified as being 
of “moderate quality”, 16 (24%) studies were rated as “low 
quality” and four studies (6%) as “high quality” (Fig. 3; Sup-
plementary Table 2). Key limitations representing risk of 
bias included inadequate details of the time period used to 
identify and recruit participants, use of non-blinded evalua-
tors and lack of quality control data for the methods used to 
compare MS-HF with MS-LF.
Neuroimaging Meta‑Analyses
Brain Volume
Meta-analysis suggested a reduction in mean normal-
ised brain volume ( 22.74 ml; 95% CI: -37.72 to -7.76 ml; 
p = 0.003) in MS-HF versus MS-LF, accompanied by a 
reduction in the volume of grey matter in MS-HF versus 
MS-LF ( 18.81 ml; 95% CI:  29.60 to  8.03 ml; p < 0.001). 
There was no significant difference in white matter volume 
between MS-HF and MS-LF (-6.41 ml; 95% CI: -13.98 to 
1.15 ml; p = 0.10). Larger reductions in mean normalised 
brain volume, grey and white matter volumes (all p < 0.001) 
were apparent for MS-LF and MS-HF versus HC (Tables 1, 
2 and 3; Supplementary Figs. 1, 2, and 3).
Subcortical Grey Matter Structure Volumes
Where data for sub-cortical structures were reported for 
the left and right sides, data were summed to provide a 
single volumetric measure for comparison with studies in 
which a single volumetric measure was reported. Meta-
analysis showed a reduction in putamen ( 0.40 ml; 95% CI: 
 0.69 to  0.10 ml; p = 0.008) and accumbens ( 0.09 ml; 95% 
CI:  0.15 to  0.03 ml; p = 0.003) volumes for MS-HF versus 
MS-LF. Larger effect-size reductions in thalamus and cau-
date volumes did not reach statistical significance because 
of wider confidence intervals and there were high levels 
of heterogeneity (I2 ≥ 89%; Fig. 2). Volumetric reductions 
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were apparent for the thalamus, putamen and caudate 
(p ≤ 0.02) in MS-LF and MS-HF versus HC, and for the 
accumbens in MS-HF versus HC (p = 0.04; Tables 1, 2 and 
3; Supplementary Figs. 1, 2, and 3).
Lesion Volume, White Matter and Axonal Integrity 
and Function
There was an increased volume of T1-weighted hypointense 
lesions in MS-HF versus MS-LF (1.10 ml; 95% CI: 0.47 to 
1.73 ml; p < 0.001) and for MS-LF and MS-HF versus HC 
(p < 0.0001). However, there were no differences between 
MS-HF and MS-LF for T2-weighted lesion volume (1.19 ml; 
95% CI: -0.43 to 2.80 ml; p = 0.15), white matter micro-
structural integrity (DTI indices of fractional anisotropy 
and mean diffusivity) or axonal integrity/function (NAA/
Cr or Cho/Cr by MRS). There was an increase in DTI mean 
diffusivity for MS-HF (0.02 ×  10−3  mm2/s; 95% CI: 0.01 
to 0.03 ×  10−3  mm2/s; p < 0.001) and MS-LF (0.03 ×  10−3 
 mm2/s; 95% CI: 0.00 to 0.06 ×  10−3  mm2/s; p = 0.03) versus 
HC, and a reduction in the NAA/Cr ratio in MS-HF ver-
sus HC (-0.10; 95% CI: -0.18 to -0.01; p < 0.03), indicating 
Table 1  Summary of the results of meta-analyses for neuroimaging and neurophysiological studies (MS-HF versus MS-LF)
Data are presented as absolute mean differences with 95% confidence intervals











Mean normalised brain volume (ml) 11 336 375 -22.74 (-37.72, -7.76) 0.003 χ2 = 7.24; p = 0.70; I2 = 0%
Brain parenchymal fraction (%) 6 129 159 0.17 (-0.54, 0.88) 0.64 χ2 = 3.03; p = 0.70;  I2 = 0%
Grey matter volume (ml) 9 306 318 -18.81 (-29.60, -8.03) 0.0006 χ2 = 5.71; p = 0.68; I2 = 0%
White matter volume (ml) 9 306 318 -6.41 (-13.98, 1.15) 0.10 χ2 = 2.94; p = 0.94;  I2 = 0%
Thalamus volume (ml) 8 234 286 -0.56 (-1.44, 0.31) 0.21 χ2 = 88.55; p < 0.00001;  I2 = 92%
Putamen volume (ml) 4 163 178 -0.40 (-0.69, -0.10) 0.008 χ2 = 4.89; p = 0.18; I2 = 39%
Caudate volume (ml) 4 163 178 -0.45 (-0.95, 0.04) 0.07 χ2 = 27.43; p < 0.00001;  I2 = 89%
Accumbens volume (ml) 2 53 59 -0.09 (-0.15, -0.03) 0.003 χ2 = 0.36; p = 0.55; I2 = 0%
Amygdala volume (ml) 2 53 59 -0.00 (-0.15, 0.14) 0.95 χ2 = 1.27; p = 0.27;  I2 = 19%
Pallidus volume (ml) 2 46 46 -0.23 (-0.50, 0.04) 0.09 χ2 = 2.90; p = 0.09;  I2 = 66%
T1-weighted Lesion volume (ml) 9 483 334 1.10 (0.47, 1.73) 0.0007 χ2 = 8.90; p < 0.35; I2 = 10%
T2-weighted lesion volume (ml) 21 730 596 1.19 (-0.43, 2.80) 0.15 χ2 = 42.25; p < 0.003;  I2 = 53%
Fractional anisotrophy 3 60 60 -0.01 (-0.02, 0.01) 0.29 χ2 = 8.99; p = 0.01;  I2 = 78%
Mean diffusivity (×  10−3  mm2/s) 3 60 60 0.01 (-0.03, 0.05) 0.72 χ2 = 9.04; p = 0.01;  I2 = 78%
NAA/Cr ratio 3 67 56 -0.12 (-0.27, 0.03) 0.11 χ2 = 7.63; p = 0.02;  I2 = 74%
Cho/Cr ratio 2 51 39 -0.02 (-0.09, 0.04) 0.48 χ2 = 0.34; p = 0.56;  I2 = 0%
Neurophysiological variables
Upper-limb MVC (N) 6 130 69 -3.55 (-7.11, 0.01) 0.05 χ2 = 3.23; p = 0.66; I2 = 0%
Lower-limb MVC (N) 4 72 55 -19.23 (-35.93, -2.53) 0.02 χ2 = 2.43; p = 0.49; I2 = 0%
Upper-Limb voluntary activation (%) 3 33 29 -5.77 (-8.61, -2.93)  < 0.0001 χ2 = 0.45, p = 0.80; I2 = 0%
Lower-limb voluntary activation (%) 3 36 29 -2.16 (-4.24, -0.07) 0.04 χ2 = 0.11; p = 0.94; I2 = 0%
Motor evoked potential threshold (%) 3 61 34 -0.05 (-5.46, 5.36) 0.99 χ2 = 3.09; p = 0.21;  I2 = 35%
Motor evoked potential amplitude (mV) 2 40 17 -0.09 (-0.42, 0.23) 0.57 χ2 = 1.18; p = 0.28;  I2 = 15%
Motor evoked potential latency (ms) 2 40 17 1.70 (-2.09, 5.50) 0.38 χ2 = 5.21; p = 0.02;  I2 = 81%
Central motor conduction time (ms) 2 32 19 -0.74 (-2.75, 1.27) 0.47 χ2 = 0.05; p = 0.82;  I2 = 0%
Short interval intracortical inhibition (%) 3 45 42 -1.06 (-30.08, 27.96) 0.94 χ2 = 10.64; p = 0.005;  I2 = 81%
Intracortical facilitation (%) 3 45 42 1.74 (-18.36, 21.84) 0.87 χ2 = 0.72; p = 0.70;  I2 = 0%
Upper-limb post-fatigue task MVC (%) 5 139 87 -5.61 (-9.57, -1.65) 0.006 χ2 = 5.04; p = 0.28; I2 = 21%
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relative impairment of microstructural and axonal integrity/
function (Tables 1, 2 and 3; Supplementary Figs. 1, 2, and 
3).
Neurophysiological Meta‑Analyses
Corticospinal Integrity and Intra‑Cortical Inhibition
There were no significant differences between MS-HF 
and MS-LF in MEP amplitude, latency, threshold, cen-
tral motor conduction time or SICI. However, higher 
MEP thresholds were apparent for MS-LF and MS-HF 
versus HC (p ≤ 0.02; Tables 1, 2 and 3; Supplementary 
Figs. 1, 2, and 3).
Skeletal Muscle Maximum Voluntary Contraction 
Force and Voluntary Activation
There were reductions in lower-limb ( -19.23 N; 95% CI: 
- 35.93 to - 2.53 N; p = 0.02) and upper-limb MVC force 
(- 3.55 N; 95% CI: - 7.11 to 0.01 N; p = 0.05) in MS-HF 
versus MS-LF, with the latter of borderline statistical 
significance. Reductions in upper-limb MVC force were 
also apparent in MS-LF and MS-HF versus HC (p ≤ 0.03). 
Meta-analysis of studies which used the twitch-interpo-
lation technique during a MVC showed reduced volun-
tary activation in MS-HF versus MS-LF for upper-limb 
( 5.77%; 95% CI: 8.61 to  2.93%; p < 0.0001) and lower-
limb skeletal muscles ( -2.16%; 95% CI: -4.24 to - 0.07%; 
p = 0.04). Upper-limb muscles included finger and thumb 
flexors/extensors and lower-limb muscles included the 
quadriceps and dorsiflexors (Tables 1, 2 and 3; Supple-
mentary Figs. 1, 2, and 3).
Motor Fatigability
Meta-analysis of the percent decline in MVC from base-
line after an upper-limb (finger or thumb flexor/extensor) 
skeletal muscle fatigue task (either sustained [N = 3] or 
intermittent [N = 2] isometric MVC) revealed greater 
Table 2  Summary of the results of meta-analyses for neuroimaging and neurophysiological studies (MS-HF versus HC)
Data are presented as absolute mean differences with 95% confidence intervals











Mean normalised brain volume (ml) 9 305 356 -74.01 (-88.86, -59.16)  < 0.00001 χ2 = 7.80; p = 0.45; I2 = 0%
Brain parenchymal fraction (%) 5 118 90 -2.06 (-3.12, -0.99) 0.0002 χ2 = 5.65; p = 0.23; I2 = 29%
Grey matter volume (ml) 8 290 343 -58.96 (-79.21, -38.72)  < 0.00001 χ2 = 27.73; p = 0.0002; I2 = 75%
White matter volume (ml) 8 290 343 -33.22 (-44.28, -22.15)  < 0.00001 χ2 = 15.68; p = 0.03; I2 = 55%
Thalamus volume (ml) 6 208 235 -1.67 (-2.25, -1.09)  < 0.00001 χ2 = 28.00; p < 0.0001; I2 = 82%
Putamen volume (ml) 4 163 148 -1.07 (-1.50, -0.63)  < 0.00001 χ2 = 10.82; p = 0.01; I2 = 72%
Caudate volume (ml) 4 163 145 -0.84 (-1.15, -0.53)  < 0.00001 χ2 = 8.95; p = 0.03; I2 = 66%
Accumbens volume (ml) 2 53 59 -0.17 (-0.34, -0.01) 0.04 χ2 = 4.19; p < 0.04; I2 = 76%
Amygdala volume (ml) 2 53 59 -0.10 (-0.56, 0.36) 0.67 χ2 = 7.08; p < 0.008;  I2 = 86%
T1-weighted lesion volume (ml) 2 49 48 4.66 (2.42, 6.90)  < 0.0001 χ2 = 3.42; p = 0.06; I2 = 71%
Fractional anisotrophy 2 45 65 -0.02 (-0.04, 0.01) 0.31 χ2 = 25.86; p < 0.00001;  I2 = 96%
Mean diffusivity (× 10−3 mm2/s) 2 45 65 0.02 (0.01, 0.03) 0.0009 χ2 = 0.00; p = 1.00; I2 = 0%
NAA/Cr ratio 2 33 27 -0.10 (-0.18, -0.01) 0.03 χ2 = 0.01; p = 0.91; I2 = 0%
Neurophysiological variables
Upper-limb MVC (N) 5 69 82 -8.73 (-16.71, -0.75) 0.03 χ2 = 9.01; p = 0.06; I2 = 56%
Lower-limb MVC (N) 2 17 29 -63.94 (-128.18, 0.31) 0.05 χ2 = 1.91; p = 0.17; I2 = 48%
Motor evoked potential threshold (%) 2 40 19 8.46 (2.73, 14.18) 0.004 χ2 = 1.75; p = 0.19; I2 = 43%
Motor evoked potential amplitude (mV) 2 40 19 -0.74 (-2.13, 0.65) 0.30 χ2 = 7.28; p = 0.007;  I2 = 86%
Motor evoked potential latency (ms) 2 40 19 2.81 (-2.09, 7.71) 0.26 χ2 = 14.24; p = 0.0002;  I2 = 93%
Short interval intracortical inhibition (%) 2 24 18 11.93 (-10.99, 34.86) 0.31 χ2 = 2.09; p = 0.15;  I2 = 52%
Intracortical facilitation (%) 2 24 18 1.67 (-22.96, 26.30) 0.89 χ2 = 1.17; p = 0.28;  I2 = 15%
Upper-limb post-fatigue task MVC (%) 4 78 109 -7.43 (-11.95, -2.90) 0.001 χ2 = 4.28; p = 0.23; I2 = 30%
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motor fatigability for MS-HF versus MS-LF ( 5.61%; 95% 
CI: -9.57 to -1.65%; p = 0.006). A more pronounced level 
of upper-limb motor fatigability was also observed for 
MS-HF versus HC ( 7.43%; 95% CI: -11.95 to -2.90%; 




Using a dichotomised model (MS-HF versus MS-LF), this 
systematic review and accompanying meta-analyses aimed to 
provide an improved insight into structural and neurophysio-
logical correlates of MS fatigue. By robustly consolidating an 
extensive and somewhat conflicting evidence-base, the results 
suggest that higher levels of MS fatigue are characterised by 
greater cortico-subcortical atrophy, and with indications of 
greater neural damage, as evidenced by an increased volume 
of T1-weighted hypointense lesions (Napoli & Bakshi, 2005). 
These neurostructural impairments appear to be accompanied 
by neurophysiological decrements, manifest as impaired MVC 
force and reduced skeletal muscle voluntary activation. As 
most studies were categorised as being of moderate quality, and 
also considering there were differences in the exact cut-points 
used to classify fatigue status across different studies, some 
level of caution is required when interpreting meta-analysis 
results. Nevertheless, the synthesis of available cross-sectional 
data from the included studies, together with published peer-
reviewed data (acquired from senior authors) that were not 
originally presented by fatigue status of PwMS, means these 
results provide the most precise effect-size estimates of neu-
robiological differences between MS-HF and MS-LF to date.
Table 3  Summary of the results of meta-analyses for neuroimaging and neurophysiological studies (MS-LF versus HC)
Data are presented as absolute mean differences with 95% confidence intervals











Mean normalised brain volume (ml) 9 333 356 -51.59 (-71.80, -31.38)  < 0.00001 χ2 = 15.57; p = 0.05; I2 = 49%
Brain parenchymal fraction (%) 5 150 90 -1.95 (-3.46, -0.44) 0.01 χ2 = 15.27; p = 0.004; I2 = 74%
Grey matter volume (ml) 8 301 343 -41.39 (-62.63, -20.16) 0.0001 χ2 = 32.39; p < 0.0001; I2 = 78%
White matter volume (ml) 8 301 343 -25.51 (-37.27, -13.76) 0.0001 χ2 = 16.43; p = 0.02; I2 = 57%
Thalamus volume (ml) 6 263 235 -1.10 (-2.13, -0.07) 0.04 χ2 = 103.20; p < 0.00001; 
I2 = 95%
Putamen volume (ml) 4 178 148 -0.65 (-0.93, -0.38)  < 0.00001 χ2 = 5.01; p = 0.17; I2 = 40%
Caudate volume (ml) 4 178 148 -0.36 (-0.66, -0.06) 0.02 χ2 = 8.48; p = 0.04; I2 = 65%
Accumbens volume (ml) 2 53 59 -0.10 (-0.31, 0.11) 0.36 χ2 = 7.18; p = 0.007;  I2 = 86%
Amygdala volume (ml) 2 53 59 -0.03 (-0.29, 0.24) 0.85 χ2 = 3.06; p = 0.08;  I2 = 67%
T1-weighted lesion volume (ml) 2 56 48 5.81 (3.93, 7.69)  < 0.00001 χ2 = 0.18; p = 0.68; I2 = 0%
Fractional anisotrophy 2 46 65 -0.02 (-0.04, -0.00) 0.04 χ2 = 11.63; p = 0.0007; I2 = 91%
Mean diffusivity (× 10−3 mm2/s) 2 46 65 0.03 (0.00, 0.06) 0.03 χ2 = 3.79; p = 0.05; I2 = 74%
NAA/Cr ratio 2 30 27 -0.05 (-0.12, 0.02) 0.19 χ2 = 0.07; p = 0.79;  I2 = 0%
Neurophysiological variables
Upper-limb MVC (N) 5 48 82 -5.33 (-8.79, -1.86) 0.003 χ2 = 2.65; p = 0.62; I2 = 0%
Lower-limb MVC (N) 2 8 29 -74.31 (-166.56, 17.93) 0.11 χ2 = 4.21; p = 0.04;  I2 = 76%
Motor evoked potential threshold (%) 2 17 19 5.60 (1.02, 10.18) 0.02 χ2 = 0.04; p = 0.84; I2 = 0%
Motor evoked potential amplitude (mV) 2 17 19 -0.33 (-1.15, 0.48) 0.42 χ2 = 2.03; p = 0.15;  I2 = 51%
Motor evoked potential latency (ms) 2 17 19 0.67 (-0.62, 1.96) 0.31 χ2 = 0.51; p = 0.47;  I2 = 0%
Short interval intracortical inhibition (%) 2 25 18 0.58 (-10.37, 11.53) 0.92 χ2 = 1.04; p = 0.31;  I2 = 4%
Intracortical facilitation (%) 2 25 18 3.90 (-40.99, 48.79) 0.86 χ2 = 3.55; p = 0.06;  I2 = 72%
Upper-limb post-fatigue task MVC (%) 4 49 109 -2.91 (-6.78, 0.96) 0.14 χ2 = 1.49; p = 0.68;  I2 = 0%
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Global and Regional Brain Volumes
Although the meta-analyses provided clear evidence of 
white matter atrophy in MS-HF and MS-LF versus HC, the 
smaller normalised brain volume in MS-HF versus MS-LF 
appears to be mainly attributable to a volumetric reduction 
in grey matter. Cortical regions with reduced volumes for 
MS-HF versus MS-LF in the included studies were the pre-
central gyrus, inferior and superior temporal gyrus, superior 
and inferior frontal gyrus, anterior cingulate gyrus, central 
sulcus, superior and inferior parietal lobules (Andreasen 
et al., 2010; Riccitelli et al., 2011; Rocca et al., 2014; Sep-
ulcre et al., 2009). This meta-analysis also consolidated the 
evidence for sub-cortical grey matter structures, revealing 
volumetric reductions in the putamen and accumbens for 
MS-HF versus MS-LF. Evidence suggests that putamen atro-
phy is present early in the MS disease cycle (Kramer et al., 
2015) and many participants recruited to the included stud-
ies are likely to have fallen into this category (EDSS ≤ 3.5 in 
over 80% of studies). Interestingly, larger effect size reduc-
tions in caudate and thalamus volumes were also observed 
in MS-HF versus MS-LF and HC but these only reached 
statistical significance for comparisons with the HC data. 
Other sub-cortical and basal ganglia structures reported 
to have reduced volumes in MS-HF versus MS-LF which 
were inversely correlated with perceived fatigue were the 
Fig. 1  PRISMA flow chart 




pallidum and superior cerebellar peduncle (Bernitsas et al., 
2017; Damasceno et al., 2016; Rocca et al., 2014) but there 
were insufficient data for meta-analyses. In addition, studies 
reported microstructural changes within the basal ganglia, 
thalamus and frontal lobe and impaired functional con-
nectivity between basal ganglia structures and the senso-
rimotor cortex, frontal, parietal and temporal lobes (Jaeger 
et al., 2018; Wilting et al., 2016). Impaired basal ganglia 
circuitry, including striatocortical and striatothalamic net-
works and potentially implicating regions that are heavily 
reliant on dopamine neurotransmission (e.g. ventral stria-
tum), have been postulated to be important mechanistic 
factors underpinning perceived MS fatigue (Chaudhuri & 
Behan, 2000; Dobryakova et al., 2015). These regions are 
primarily responsible for motor control, motor planning, 
attentional control and the integration of afferent and effer-
ent information.
T1 and T2‑Weighted Lesions
MS-HF showed an increased number of T1-weighted 
hypointense lesions in comparison with MS-LF, a 
difference that was even more pronounced in comparison 
with HC. However, there was no difference in the number 
of T2-weighted lesions or DTI indices of white matter 
microstructural integrity between MS-HF and MS-LF. The 
increased number of T1-weighted hypointense lesions could 
reflect associations between MS fatigue symptoms and recently 
activated immune inflammatory pathways or irreversible path-
ological changes which are features of the disease (Morris 
et al., 2016). Recently formed T1-weighted scan-identified 
hypointense lesions represent current disease activity, 
including reversible oedema, inflammation, demyelination 
and remyelination, whereas chronic T1-weighted hypointense 
lesions reflect irreversible demyelination and axonal loss 
(Napoli & Bakshi, 2005). In contrast, T2-weighted scan-
identified lesions, which are non-specific for the underlying 
pathology, reflect the accumulated lesion load or “burden of 
disease” (Sinnecker et al., 2012) and occur throughout the 
brain and white matter, but less commonly, the grey matter 
(Napoli & Bakshi, 2005). Nevertheless, the possibility that 
localised white matter atrophy and loss of white matter 
microstructural integrity within specific brain regions could 
influence MS fatigue symptoms should not be overlooked. 
Consistent with this observation, there is evidence that atrophy 
progression within the corpus callosum (largest collection of 
brain white matter) is implicated in the evolution of MS-related 
fatigue (Yaldizli et al., 2010). Furthermore, other studies 
have provided evidence of localised metabolic alterations or 
anisotropic changes in white matter adjacent to the lateral and 
medial pre-frontal cortex and in fibres connecting basal ganglia 
structures (Hanken et al., 2015).
Muscle Strength
Meta-analysis revealed a reduction in muscle strength 
(MVC) in MS-HF versus MS-LF, which consolidates 
a conflicting body of data on this measure from studies 
investigating PwMS (irrespective of fatigue status) versus 
HC (Zijdewind et al., 2016). Greater cortico-subcortical 
grey matter atrophy or structural damage in MS-HF ver-
sus MS-LF could have a more pronounced effect on neural 
transmission from the brain to active skeletal muscles, and 
this could account for the reduced MVC. Rocca et al. (2012) 
reported a more diffuse pattern of spinal cord interneuron 
activation in the axial and longitudinal planes in MS-HF 
versus MS-LF, which they speculated could be attributable 
to abnormally functioning local circuits, altered modulation 
from supraspinal pathways or local and remote structural 
damage (Rocca et al., 2012). However, findings from our 
meta-analyses suggest that the relative integrity of corti-
cospinal motor pathways is similar in MS-HF and MS-LF, as 
there were no differences in MEP variables or central motor 
conduction time between the groups. In contrast, a signifi-
cant increase in MEP threshold was apparent for MS-HF 
and MS-LF versus HC, consolidating inconsistent data from 
previous studies on this measure of corticospinal excitability 
(Zijdewind et al., 2016).
Voluntary Activation
Our meta-analyses revealed clear evidence of impaired 
voluntary activation (central motor drive) in MS-HF ver- 
sus MS-LF, suggesting MS-HF have a relatively impaired 
ability to fully activate skeletal muscles in comparison with 
MS-LF. This may explain the observed reduction in MVC 
in MS-HF versus MS-LF, as previous studies have reported 
significant correlations between the decline in MVC and 
voluntary activation during sustained muscular contractions 
in PwMS (Zijdewind et al., 2016). Although females are 
reported to record lower voluntary activation (and MVC) 
values than males (Solianik et al., 2017), the higher female 
to male ratio in the included studies is unlikely to account 
for these findings, as MS-HF and MS-LF comparison groups 
tended to be well-balanced for sex. An alternative explana-
tion for the lower voluntary activation (and MVC) scores 
in MS-HF could be the deconditioning effects of relative 
physical inactivity after an MS diagnosis, which may be fur-
ther compounded by the experience of severe MS fatigue 
(Sebastiao et al., 2017). Relative inactivity leads to disuse 
atrophy and neurophysiological changes affecting skeletal 
muscle voluntary activation, leading to impaired muscular 
strength and function (Rice et al., 1992). In turn, this could 
increase the amount of effort required for everyday tasks, 
thus exacerbating perceived fatigue and motor fatigability.
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Cho/Cr: 2 studies; 51 MS-HF vs 39 MS-LF
NAA/Cr: 3 studies; 67 MS-HF vs 56 MS-LF
Mean diffusivity (×10−3 mm2/s): 3 studies; 60 MS-HF vs 60 MS-LF
Fractional anisotrophy: 3 studies; 60 MS-HF vs 60 MS-LF
T2-WLV (ml): 21 studies; 730 MS-HF vs 596 MS-LF
T1-WLV (ml):9 studies; 483 MS-HF vs 334 MS-LF
Pallidus volume (ml):2 studies; 46 MS-HF vs 46 MS-LF
Amygdala volume (ml):2 studies; 53 MS-HF vs 59 MS-LF
Accumbens volume (ml):2 studies; 53 MS-HF vs 59 MS-LF
Caudate volume (ml): 4 studies; 163 MS-HF vs 178 MS-LF
Putamen volume (ml): 4 studies; 163 MS-HF vs 178 MS-LF
Thalamas volume (ml):8 studies; 234 MS-HF vs 286 MS-LF
WMV (ml): 9 studies; 306 MS-HF vs 318 MS-LF
GMV (ml): 9 studies: 306 MS-HF vs 318 MS-LF
BPF (%): 6 studies; 129 MS-HF vs 159 MS-LF
TBV (ml): 11 studies; 336 MS-HF vs 375 MS-LF
Neuroimaging studies
Reduced Increased
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UL fatigability (% baseline MVC): 5 studies; 139 MS-HF vs 87 MS-LF
ICF (%): 3 studies; 45 MS-HF vs 42 MS-LF
SICI (%): 3 studies; 45 MS-HF vs 42 MS-LF
CMCT (ms): 2 studies; 32 MS-HF vs 19 MS-LF
MEP latency (ms): 2 studies; 40 MS-HF vs 17 MS-LF
MEP amplitude (mV): 2 studies; 40 MS-HF vs 17 MS-LF
MEP threshold (%): 3 studies; 61 MS-HF vs 34 MS-LF
LL VA (%): 3 studies; 36 MS-HF vs 29 MS-LF
UL VA (%): 3 studies; 33 MS-HF vs 29 MS-LF
LL MVC (N): 4 studies; 72 MS-HF vs 55 MS-LF






Current data provides no clear evidence of a link between 
MS fatigue and altered intracortical inhibition (SICI) or 
intracortical facilitation (ICF), despite reports of altered 
functional connectivity and hyperactivation in fronto-parietal 
cortical regions, sensorimotor network and subcortical areas 
important for motor, sensory and cognitive processing in 
MS-HF (Bisecco et al., 2017; Jaeger et al., 2018; Rocca et al., 
2016; Specogna et al., 2012; Tartaglia et al., 2008). Evidence 
from fMRI and EEG studies suggests that functional 
reorganisation within cortico-subcortical networks as a 
compensatory response to MS brain lesions could account 
for an increased energy demand for neural processing within 
certain networks (Filippi & Rocca, 2004; Kos et al., 2008). 
This could at least partially explain increased perceptions 
of fatigue in PwMS because of an elevated demand on 
functioning neural circuits. However, at present very few 
studies have compared SICI or ICF variables between MS-HF 
and MS-LF, making it difficult to draw conclusions about 
the extent to which modulation of intracortical inhibitory or 
facilitatory networks could be implicated in MS fatigue. The 
limited conflicting data that is currently available for SICI 
may be a reflection of different MS populations studied, as 
two of the published studies were focused on people with 
relapsing–remitting MS (Liepert et al., 2005; Morgante 
et al., 2011), whereas a third was focused on progressive 
MS (Chalah et al., 2019).
Upper‑ and Lower‑Limb Motor Fatigability
Meta-analysis of five studies revealed an increased level of 
upper-limb motor fatigability for MS-HF versus MS-LF, 
showing a more pronounced decline in force production. 
In contrast, only one of the included studies with a 
small sample size (N = 9) compared lower-limb motor 
fatigability between MS-HF and MS-LF (Ng et al., 2000) 
using a sustained 30% MVC dorsi-flexor protocol. There 
is no standardised method for assessing motor fatigability 
(Severijns et al., 2017) and this is reflected in the broad 
range of protocols used in comparisons of PwMS versus 
HC. It is also acknowledged that motor fatigability is task 
specific, being influenced by task complexity (Wolkorte 
et  al., 2015), and that heterogeneity between patients 
(attributable to MS-specific functional impairments 
and differences in motor control) can confound motor 
fatigability measures (Severijns et al., 2017). However, aside 
from measurement of force decline over time, consistent 
motor fatigability data for MS-HF versus MS-LF have 
been reported in studies that have used exercise duration 
and number of muscular contractions before reaching a 
fatigue criterion (Liepert et al., 2005; Perretti et al., 2004). 
Evidence suggests that motor fatigability resulting from a 
sustained voluntary muscle contraction in PwMS mainly 
results from a decline in voluntary activation (suggesting 
central fatigue mechanisms), whereas in healthy controls 
motor fatigability seems to be mainly of peripheral origin 
(peripheral fatigue mechanisms) at the level of skeletal 
muscle (Severijns et al., 2017; Sheean et al., 1997; Steens 
et al., 2012b). An elegant study that combined imaging and 
electrophysiological techniques showed that in PwMS there 
was an inability to increase cortical activation in response to 
motor fatigability-related changes downstream of the motor 
cortex, which was at odds with the increase in cortical 
activation observed in HC (Steens et al., 2012b). Our meta-
analysis of upper-limb data suggests that MS-HF may have 
less ability than MS-LF to increase cortical activation as 
a compensatory response to peripheral fatigue and this 
warrants further study. In addition, the relative paucity of 
lower-limb studies needs to be addressed, as PwMS more 
commonly report issues of motor fatigability in relation 
to lower-limb activities such as walking (Severijns et al., 
2017).
Fig. 2  Summary of results of meta-analyses comparing neuroim-
aging and neurofunctional data for MS-HF versus MS-LF. Data are 
presented as standardised mean difference and 95% confidence inter-
vals. The upper figure presents summary data for neuroimaging vari-
ables and the lower figure presents summary data for neurofunctional 
variables, with the abscissas representing a decrease or increase for 
MS-HF in comparison with MS-LF. TBV, total brain volume; BPF, 
brain parenchymal fraction; GMV, gray matter volume, WMV, white 
matter volume, T1-WLV, T1-weighted lesion volume, T2-WLV, 
T2-weighted lesion volume, NAA/Cr, N-acetylaspartate to creatine 
ratio Cho/Cr, choline to creatine ratio, UL, upper-limb; LL, lower-
limb; MEP, motor evoked potential; CMCT, central motor conduction 
time; SICI, short-interval intracortical inhibition, ICF, intracortical 
facilitation; MVC, maximum voluntary contraction force
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Fig. 3  Methodological quality of the included studies evaluated using 
the Cross-Sectional/Prevalence Study Quality Scale, recommended 
by the Agency for Healthcare Research and Quality (AHRQ). Scores 





Key limitations of this meta-analysis include the diversity 
of MRI techniques used for neuroimaging studies and het-
erogeneity of methods used to assess self-reported perceived 
fatigue and motor fatigability. Furthermore, many studies 
collected either neuroimaging or neurophysiological data, 
which prevented an exploration of relationships between 
neuroanatomical and neurophysiological impairments 
(including the impact on motor fatigability measures) within 
the same participants. The broad-ranging patient character-
istics and lack of participant ethnicity data across differ-
ent studies may also be considered as a limitation, although 
confounders such as disease severity, level of disability, sex 
and age were minimised in the larger data-set meta-analyses. 
Nevertheless, some of the meta-analyses included a 
small number of studies and as the overall quality rating of 
included studies was ‘moderate’, as such, caution is needed 
when interpreting these results. In addition, although the 
Agency for Healthcare Research and Quality (Zeng et al., 
2015) is suitable for use in systematic reviews of cross-
sectional studies, there is no obvious candidate tool for 
assessing the quality of observational/cross-sectional stud-
ies, which may be considered a study limitation. Finally, 
the method used to differentiate MS-HF and MS-LF in the 
included studies was based on previously published cut-
points for the FSS and MFIS that rely on recollections of 
fatigue experiences over the previous 1–4 weeks. Fatigue can 
be sporadic and the intensity of fatigue symptoms amongst 
PwMS at the time of testing was not well-documented in 
many studies. In addition, differences in the exact cut-points 
used to distinguish MS-HF from MS-LF across different 
studies have to be taken into account when interpreting 
meta-analysis data based on dichotomised categories.
Conclusion
In conclusion, this is the first meta-analysis to synthesise 
published cross-sectional data on structural and neurophysi-
ological measures between MS-HF and MS-LF. The results 
suggest that higher levels of MS fatigue are characterised 
by greater cortico-subcortical grey matter atrophy and brain 
lesions, reduced muscular strength, reduced central drive 
(voluntary activation), and increased upper-limb motor 
fatigability. By consolidating an extensive and somewhat 
conflicting evidence-base, the meta-analysis provides new 
insights into neurobiological differences that exist between 
MS-HF and MS-LF.
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